+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Hypogonadism

  • ID: 4775116
  • Report
  • November 2019
  • Region: Global
  • 36 pages
  • Datamonitor Healthcare
1 of 3

FEATURED COMPANIES

  • AbbVie
  • Apricus
  • Forendo
  • GlaxoSmithKline
  • MORE
This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, key upcoming and regulatory events, probability of success, patent information, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta. These are commonly administered via the transdermal route, with a smaller number of products being available in oral, intramuscular, intranasal, sublingual/oral transmucosal, subcutaneous, and topical formulations.
  • The largest proportion of industry-sponsored drugs in active clinical development for hypogonadism are in Phase II, with only one drug in the NDA/BLA phase.
  • Therapies in development for hypogonadism focus on targets such as androgen receptors, estrogen receptor alpha, estrogen receptor beta, gonadotropin-releasing hormone, and aromatase. The majority of the pipeline drugs are administered via the oral route, with the remainder being subcutaneous and transdermal formulations.
  • An expected PDUFA date for Tlando is the only high-impact upcoming event in the hypogonadism space. The overall likelihood of approval of a Phase I endocrine-other asset is 23.6%, and the average probability a drug advances from Phase III is 77.4%. Drugs, on average, take 9.2 years from Phase I to approval, compared to 9.1 years in the overall endocrine space.
  • There have been 16 licensing and asset acquisition deals involving hypogonadism drugs during 2014-19. The $317.5m exclusive license agreement signed in 2014 between Apricus and Forendo for fispemifene, an investigational treatment for urological conditions in men, was the largest deal.
  • The distribution of clinical trials across Phase I-IV indicates that trials for hypogonadism have been evenly split between the early and late phases of development, with 51% of trials in Phase I-II and 49% in Phase III-IV.
  • The US has a substantial lead in the number of hypogonadism clinical trials globally. The UK leads the major EU markets, while India has the top spot in Asia.
  • Clinical trial activity in the hypogonadism space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for hypogonadism, with eight trials.
  • AbbVie leads industry sponsors with the highest overall number of clinical trials for hypogonadism, followed by GlaxoSmithKline
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Apricus
  • Forendo
  • GlaxoSmithKline
  • MORE
1. Overview

2. Key Takeaways

3. Disease Background
  • Subtypes
4. Treatment
  • Treatment of hypogonadism in females
  • Treatment of hypogonadism in males
5. Epidemiology

6. Marketed Drugs

7. Pipeline Drugs

8. Recent Events and Analyst Opinion
  • Multiple Drugs for Hypogonadism (June 25, 2019)
  • Tlando for Hypogonadism (March 27, 2019)
  • Tlando for Hypogonadism (May 9, 2018)
9. Key Upcoming Events

10. Key Regulatory Events
  • Tlando NDA Slated For Fall Action Following Resubmission
  • Surprise Approval For Clarus’s Oral Testosterone Includes Black Box, No REMS
11. Probability of Success

12. Licensing and Asset Acquisition Deals

13. Parent Patents

14. Revenue Opportunity

15. Clinical Trial Landscape
  • Sponsors by status
  • Sponsors by phase
16. Bibliography
  • Prescription information
17. Appendix

List of Figures
Figure 1: Overview of pipeline drugs for hypogonadism in the US
Figure 2: Pipeline drugs for hypogonadism, by company
Figure 3: Pipeline drugs for hypogonadism, by drug type
Figure 4: Pipeline drugs for hypogonadism, by classification
Figure 5: Tlando for Hypogonadism (March 27, 2019): Phase III - Ambulatory Blood Pressure Study (ABPM)
Figure 6: Key upcoming events in hypogonadism
Figure 7: Probability of success in the hypogonadism pipeline
Figure 8: Licensing and asset acquisition deals in hypogonadism, 2014–19
Figure 9: Parent patents in hypogonadism
Figure 10: Clinical trials in hypogonadism
Figure 11: Top 10 drugs for clinical trials in hypogonadism
Figure 12: Top 10 companies for clinical trials in hypogonadism
Figure 13: Trial locations in hypogonadism
Figure 14: Hypogonadism trials status
Figure 15: Hypogonadism trials sponsors, by phase

List of Tables
Table 1: Marketed drugs for hypogonadism
Table 2: Pipeline drugs for hypogonadism in the US
Table 3: Multiple Drugs for Hypogonadism (June 25, 2019)
Table 4: Tlando for Hypogonadism (March 27, 2019)
Table 5: Tlando for Hypogonadism (May 9, 2018)
Table 6: Historical global sales, by drug ($m), 2014–18
Table 7: Forecasted global sales, by drug ($m), 2019–23
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie
  • Apricus
  • Forendo
  • GlaxoSmithKline
Note: Product cover images may vary from those shown
Adroll
adroll